Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

The NHLBI REVIVE-IT study: Understanding its discontinuation in the context of current left ventricular assist device therapy.

Pagani FD, Aaronson KD, Kormos R, Mann DL, Spino C, Jeffries N, Taddei-Peters WC, Mancini DM, McNamara DM, Grady KL, Gorcsan J 3rd, Petrucci R, Anderson AS, Glick HA, Acker MA, Eduardo Rame J, Goldstein DJ, Pamboukian SV, Miller MA, Timothy Baldwin J; REVIVE-IT Investigators.

J Heart Lung Transplant. 2016 Nov;35(11):1277-1283. doi: 10.1016/j.healun.2016.09.002. Epub 2016 Oct 6.

PMID:
27836022
2.

A hybrid effectiveness-implementation cluster randomized trial of group CBT for anxiety in urban schools: rationale, design, and methods.

Eiraldi R, Khanna MS, Jawad AF, Fishman J, Glick HA, Schwartz BS, Cacia J, Wandersman A, Beidas R.

Implement Sci. 2016 Jul 12;11:92. doi: 10.1186/s13012-016-0453-z.

3.

Impact of intensive lifestyle intervention on preference-based quality of life in type 2 diabetes: Results from the Look AHEAD trial.

Zhang P, Hire D, Espeland MA, Knowler WC, Thomas S, Tsai AG, Glick HA; Look AHEAD Research Group.

Obesity (Silver Spring). 2016 Apr;24(4):856-64. doi: 10.1002/oby.21445. Epub 2016 Mar 8.

4.

The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: an analysis of the CATIE Schizophrenia Trial.

Glick HA, Li P, Harvey PD.

Schizophr Res. 2015 Aug;166(1-3):110-4. doi: 10.1016/j.schres.2015.05.021. Epub 2015 Jun 2.

PMID:
26044113
5.

Comparative effectiveness and cost-effectiveness analyses frequently agree on value.

Glick HA, McElligott S, Pauly MV, Willke RJ, Bergquist H, Doshi J, Fleisher LA, Kinosian B, Perfetto E, Polsky DE, Schwartz JS.

Health Aff (Millwood). 2015 May;34(5):805-11. doi: 10.1377/hlthaff.2014.0552.

PMID:
25941282
6.

Low Health Literacy Predicts Misperceptions of Diabetes Control in Patients With Persistently Elevated A1C.

Ferguson MO, Long JA, Zhu J, Small DS, Lawson B, Glick HA, Schapira MM.

Diabetes Educ. 2015 Jun;41(3):309-19. doi: 10.1177/0145721715572446. Epub 2015 Feb 19.

PMID:
25699568
7.

Re-examining the BMI threshold for bariatric surgery in the USA.

Choudhury RA, Murayama KM, Neylan CJ, Savulionyte G, Glick HA, Williams NN, Dempsey DT, Dumon KR.

J Gastrointest Surg. 2014 Dec;18(12):2074-9. doi: 10.1007/s11605-014-2653-7. Epub 2014 Oct 9.

PMID:
25297444
8.

Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: the action for health in diabetes.

Espeland MA, Glick HA, Bertoni A, Brancati FL, Bray GA, Clark JM, Curtis JM, Egan C, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Hazuda HP, Hill JO, Hire D, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Killean T, Kitabchi AE, Knowler WC, Kriska A, Lewis CE, Miller M, Montez MG, Murillo A, Nathan DM, Nyenwe E, Patricio J, Peters AL, Pi-Sunyer X, Pownall H, Redmon JB, Rushing J, Ryan DH, Safford M, Tsai AG, Wadden TA, Wing RR, Yanovski SZ, Zhang P; Look AHEAD Research Group.

Diabetes Care. 2014 Sep;37(9):2548-56. doi: 10.2337/dc14-0093.

9.

Roux-en-Y gastric bypass compared with aggressive diet and exercise therapy for morbidly obese patients awaiting renal transplant: a decision analysis.

Choudhury RA, Murayama KM, Abt PL, Glick HA, Naji A, Williams NN, Dumon KR.

Surg Obes Relat Dis. 2014 Jan-Feb;10(1):79-87. doi: 10.1016/j.soard.2013.04.016. Epub 2013 May 23.

PMID:
24139923
10.

Cost-effectiveness of a primary care intervention to treat obesity.

Tsai AG, Wadden TA, Volger S, Sarwer DB, Vetter M, Kumanyika S, Berkowitz RI, Diewald LK, Perez J, Lavenberg J, Panigrahi ER, Glick HA.

Int J Obes (Lond). 2013 Aug;37 Suppl 1:S31-7. doi: 10.1038/ijo.2013.94.

11.

Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: a cohort study.

Margolis DJ, Gupta J, Hoffstad O, Papdopoulos M, Glick HA, Thom SR, Mitra N.

Diabetes Care. 2013 Jul;36(7):1961-6. doi: 10.2337/dc12-2160. Epub 2013 Feb 19.

12.

Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis.

Dewitt EM, Li Y, Curtis JR, Glick HA, Greenberg JD, Anstrom KJ, Kremer JM, Reed G, Schulman KA, Reed SD.

J Rheumatol. 2013 Feb;40(2):127-36. doi: 10.3899/jrheum.120400. Epub 2013 Jan 15.

PMID:
23322461
13.

Clinical effectiveness, access to, and satisfaction with care using a telehomecare substitution intervention: a randomized controlled trial.

Bowles KH, Hanlon AL, Glick HA, Naylor MD, O'Connor M, Riegel B, Shih NW, Weiner MG.

Int J Telemed Appl. 2011;2011:540138. doi: 10.1155/2011/540138. Epub 2011 Dec 1.

14.

Sample size and power for cost-effectiveness analysis (Part 2): the effect of maximum willingness to pay.

Glick HA.

Pharmacoeconomics. 2011 Apr;29(4):287-96. doi: 10.2165/11585080-000000000-00000.

PMID:
21395349
15.

Sample size and power for cost-effectiveness analysis (part 1).

Glick HA.

Pharmacoeconomics. 2011 Mar;29(3):189-98. doi: 10.2165/11585070-000000000-00000.

PMID:
21309615
16.

Estimation and validation of a multiattribute model of Alzheimer disease progression.

Stallard E, Kinosian B, Zbrozek AS, Yashin AI, Glick HA, Stern Y.

Med Decis Making. 2010 Nov-Dec;30(6):625-38. doi: 10.1177/0272989X10363479.

17.

What do international pharmacoeconomic guidelines say about economic data transferability?

Barbieri M, Drummond M, Rutten F, Cook J, Glick HA, Lis J, Reed SD, Sculpher M, Severens JL; ISPOR Good Research Practices Economic Data Transferability Task Force.

Value Health. 2010 Dec;13(8):1028-37. doi: 10.1111/j.1524-4733.2010.00771.x.

18.

Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial.

Polsky D, Glick HA, Yang J, Subramaniam GA, Poole SA, Woody GE.

Addiction. 2010 Sep;105(9):1616-24. doi: 10.1111/j.1360-0443.2010.03001.x. Epub 2010 Jul 12.

19.

Direct medical cost of overweight and obesity in the USA: a quantitative systematic review.

Tsai AG, Williamson DF, Glick HA.

Obes Rev. 2011 Jan;12(1):50-61. doi: 10.1111/j.1467-789X.2009.00708.x. Review.

20.

What's in a perspective?

Glick HA.

Value Health. 2010 Jan-Feb;13(1):2. doi: 10.1111/j.1524-4733.2009.00674.x. Epub 2009 Nov 12. No abstract available.

21.

Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report.

Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, Reed SD, Rutten F, Sculpher M, Severens J.

Value Health. 2009 Jun;12(4):409-18. doi: 10.1111/j.1524-4733.2008.00489.x. Epub 2009 Jan 12.

22.

Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank.

DeWitt EM, Lin L, Glick HA, Anstrom KJ, Schulman KA, Reed SD.

Clin Ther. 2009 Aug;31(8):1871-80; discussion 1858. doi: 10.1016/j.clinthera.2009.08.020.

23.

Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study.

Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PM, Jones PW, Vestbo J; TOwards a Revolution in COPD Health (TORCH) investigators.

Eur Respir J. 2010 Mar;35(3):532-9. doi: 10.1183/09031936.00153108. Epub 2009 Aug 28.

24.

A randomized, controlled trial of financial incentives for smoking cessation.

Volpp KG, Troxel AB, Pauly MV, Glick HA, Puig A, Asch DA, Galvin R, Zhu J, Wan F, DeGuzman J, Corbett E, Weiner J, Audrain-McGovern J.

N Engl J Med. 2009 Feb 12;360(7):699-709. doi: 10.1056/NEJMsa0806819.

25.

Caregivers' assessments of preference-based quality of life in Alzheimer's disease.

Karlawish JH, Zbrozek A, Kinosian B, Gregory A, Ferguson A, Low DV, Glick HA.

Alzheimers Dement. 2008 May;4(3):203-11. doi: 10.1016/j.jalz.2007.11.018. Epub 2008 Apr 24.

PMID:
18631969
26.

Preference-based quality of life in patients with Alzheimer's disease.

Karlawish JH, Zbrozek A, Kinosian B, Gregory A, Ferguson A, Glick HA.

Alzheimers Dement. 2008 May;4(3):193-202. doi: 10.1016/j.jalz.2007.11.019. Epub 2008 May 2.

PMID:
18631968
27.

Age inconsistency in the American Academy of Pediatrics guidelines for acute otitis media.

Meropol SB, Glick HA, Asch DA.

Pediatrics. 2008 Apr;121(4):657-68. doi: 10.1542/peds.2007-1913.

PMID:
18381528
28.

A critical comparison of clinical decision instruments for computed tomographic scanning in mild closed traumatic brain injury in adolescents and adults.

Stein SC, Fabbri A, Servadei F, Glick HA.

Ann Emerg Med. 2009 Feb;53(2):180-8. doi: 10.1016/j.annemergmed.2008.01.002. Epub 2008 Mar 14.

PMID:
18339447
29.

Clinical trial-based cost-effectiveness analyses of antipsychotic use.

Polsky D, Doshi JA, Bauer MS, Glick HA.

Am J Psychiatry. 2006 Dec;163(12):2047-56. Review.

PMID:
17151153
30.

Indications for CT scanning in mild traumatic brain injury: A cost-effectiveness study.

Stein SC, Burnett MG, Glick HA.

J Trauma. 2006 Sep;61(3):558-66. Review. Erratum in: J Trauma. 2007 May;62(5):1309.

PMID:
16966987
31.

Analyses of cost data in economic evaluations conducted alongside randomized controlled trials.

Doshi JA, Glick HA, Polsky D.

Value Health. 2006 Sep-Oct;9(5):334-40. Review.

32.
33.

Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.

DeWitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F.

Arch Intern Med. 2006 Jan 9;166(1):57-63. Erratum in: Arch Intern Med. 2006 May 8;166(9):954.

PMID:
16401811
34.

Cost-effectiveness of a low-carbohydrate diet and a standard diet in severe obesity.

Tsai AG, Glick HA, Shera D, Stern L, Samaha FF.

Obes Res. 2005 Oct;13(10):1834-40.

35.

Conducting economic evaluations alongside multinational clinical trials: toward a research consensus.

Reed SD, Anstrom KJ, Bakhai A, Briggs AH, Califf RM, Cohen DJ, Drummond MF, Glick HA, Gnanasakthy A, Hlatky MA, O'Brien BJ, Torti FM Jr, Tsiatis AA, Willan AR, Mark DB, Schulman KA.

Am Heart J. 2005 Mar;149(3):434-43.

PMID:
15864231
36.

Clinical nurse specialist care managers' time commitments in a disease-management program for bipolar disorder.

Glick HA, Kinosian B, McBride L, Williford WO, Bauer MS; CSP #430 Study Team.

Bipolar Disord. 2004 Dec;6(6):452-9.

PMID:
15541060
37.

A manic-depressive symptom self-report in optical scanable format.

Glick HA, McBride L, Bauer MS.

Bipolar Disord. 2003 Oct;5(5):366-9.

PMID:
14525558
38.

Factors affecting decisions to seek treatment for sick children in Kerala, India.

Pillai RK, Williams SV, Glick HA, Polsky D, Berlin JA, Lowe RA.

Soc Sci Med. 2003 Sep;57(5):783-90.

PMID:
12850106
39.

Design and analysis of unit cost estimation studies: How many hospital diagnoses? How many countries?

Glick HA, Orzol SM, Tooley JF, Polsky D, Mauskopf JO.

Health Econ. 2003 Jul;12(7):517-27. Review.

PMID:
12825205
40.

Economic evaluation of breast cancer treatment: considering the value of patient choice.

Polsky D, Mandelblatt JS, Weeks JC, Venditti L, Hwang YT, Glick HA, Hadley J, Schulman KA.

J Clin Oncol. 2003 Mar 15;21(6):1139-46.

PMID:
12637482
41.

Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.

Schulman KA, Stadtmauer EA, Reed SD, Glick HA, Goldstein LJ, Pines JM, Jackman JA, Suzuki S, Styler MJ, Crilley PA, Klumpp TR, Mangan KF, Glick JH.

Bone Marrow Transplant. 2003 Feb;31(3):205-10.

PMID:
12621482
42.
43.

Preference-based quality-of-life in patients with Parkinson's disease.

Siderowf A, Ravina B, Glick HA.

Neurology. 2002 Jul 9;59(1):103-8.

PMID:
12105315
44.

Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure.

Glick HA, Orzol SM, Tooley JF, Remme WJ, Sasayama S, Pitt B.

Cardiovasc Drugs Ther. 2002 Jan;16(1):53-9.

45.
46.

Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.

Polsky D, Onesirosan P, Bauer MS, Glick HA.

J Clin Psychiatry. 2002 Feb;63(2):156-64.

PMID:
11874218
48.

Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis.

Beutels P, Edmunds WJ, AntoƱanzas F, De Wit GA, Evans D, Feilden R, Fendrick AM, Ginsberg GM, Glick HA, Mast E, PƩchevis M, Van Doorslaer EK, van Hout BA; Viral Hepatitis Prevention Board.

Pharmacoeconomics. 2002;20(1):1-7. Review.

PMID:
11817988
49.

Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses.

Glick HA, Briggs AH, Polsky D.

Expert Rev Pharmacoecon Outcomes Res. 2001 Oct;1(1):25-36. doi: 10.1586/14737167.1.1.25.

PMID:
19807505
50.

Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial.

Li Z, Willke RJ, Pinto LA, Rittenhouse BE, Rybak MJ, Pleil AM, Crouch CW, Hafkin B, Glick HA.

Pharmacotherapy. 2001 Mar;21(3):263-74.

PMID:
11256381

Supplemental Content

Loading ...
Support Center